Iovance Biotherapeutics Inc (GB:0JDK)

Iovance Biotherapeutics Financial Statements


Iovance Biotherapeutics Financial Overview

Iovance Biotherapeutics's market cap is currently ―. The company's EPS TTM is $-2.401; its P/E ratio is -4.03; Iovance Biotherapeutics is scheduled to report earnings on November 9, 2022, and the estimated EPS forecast is $-0.64. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Mar 22Dec 21Sep 21Jun 21
Income Statement
Total Revenue$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit$ ―$ ―$ ―$ ―$ ―
EBIT$ -99.73M$ -91.71M$ -99.47M$ -86.24M$ -81.43M
EBITDA$ -94.49M$ -86.73M$ -87.25M$ -85.21M$ -81.43M
Net Income Common Stockholders$ -99.35M$ -91.61M$ -99.33M$ -86.12M$ -81.35M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 424.46M$ 482.19M$ 504.41M$ 576.45M$ 593.93M
Total Assets$ 610.88M$ 701.25M$ 777.33M$ 828.83M$ 852.79M
Total Debt$ 8.14M$ 50.43M$ 53.76M$ 54.37M$ 72.21M
Net Debt$ -416.32M$ -431.76M$ -450.65M$ -522.08M$ -521.72M
Total Liabilities$ 138.19M$ 149.26M$ 155.67M$ 130.50M$ 108.38M
Stockholders Equity$ 472.69M$ 551.99M$ 621.66M$ 647.43M$ 656.50M
Cash Flow
Free Cash Flow$ -82.21M$ -85.24M$ -61.42M$ -67.38M$ -63.62M
Operating Cash Flow$ -77.64M$ -73.80M$ -53.85M$ -57.69M$ -54.01M
Investing Cash Flow$ 95.76M$ 86.52M$ 69.34M$ 12.75M$ -159.16M
Financing Cash Flow$ -2.07M$ 1.42M$ 4.15M$ 20.77M$ 163.98M
Currency in USD

Iovance Biotherapeutics Earnings and Revenue History

Iovance Biotherapeutics Debt to Assets

Iovance Biotherapeutics Cash Flow

Iovance Biotherapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis